Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: Case report and literature review

► An increased risk for developing demyelinating diseases has been reported in IBD patients. ► This is the first case of GBS developing in a IBD patient following ADA use. ► Patients receiving TNF-α antagonists should be monitored for neurologic signs and symptoms suggestive of demyelinating disease.